Joint EANM/SNMMI/IHPBA procedure guideline for $[^{99m}Tc]$Tc-mebrofenin hepatobiliary scintigraphy SPECT/CT in the quantitative assessment of the future liver remnant function

Authors:

Pieter J.W. Arntz,1,2 Christophe M. Deroose,3 Charles Marcus,4 Christian Sturesson5, Fabrizio Panaro6, Joris Erdmann1,2, Nevena Manevska7, Renee Moadel8, Lioe-Fee de Geus-Oei9,10,11, Roel J. Bennink2,12

1. Department of Surgery, Amsterdam UMC, University of Amsterdam, the Netherlands
2. Cancer Center Amsterdam, the Netherlands
3. Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven; Leuven, Belgium
4. Division of Nuclear Medicine and Molecular Imaging, department of radiology, Emory University school of medicine, Atlanta, GA, USA.
5. Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
6. Department of Surgery/Division of HBP Surgery & Transplantation. Saint Eloi Hospital, Montpellier University Hospital - School of Medicine, 34000-Montpellier, France
7. Institute of Pathophysiology and Nuclear medicine, Acad Isak S. Tadzer, Skopje, Macedonia.
8. Division of Neuroradiology, Department of Radiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York
9. Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands
10. Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands
11. Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands
12. Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands
Abstract

Purpose The aim of this joint EANM/SNMMI/IHPBA procedure guideline is to provide general information and specific recommendations and considerations on the use of $[^{99m}Tc]$Tc-mebrofenin hepatobiliary scintigraphy (HBS) in the quantitative assessment and risk analysis before surgical intervention, selective internal radiation therapy (SIRT) or before and after liver regenerative procedures. Although the gold standard to predict future liver remnant (FLR) function remains volumetry, the increasing interest in HBS and the continuous request for implementation in major liver centers worldwide, demands standardization.

Methods This guideline concentrates on the endorsement of a standardized protocol for HBS elaborates on the clinical indications, interactions, acquisition, post-processing analysis, interpretation, clinical appliance and considerations. Referral to the practical guidelines for additional post-processing manual instructions is provided.

Conclusion The increasing interest of major liver centers worldwide in HBS requires guidance for implementation. Standardization facilitates applicability of HBS and in turn promotes global implementation. Inclusion of HBS in standard care is not meant as substitute for volumetry, but rather complements risk evaluation and potentially identifies high-risk patients prone to develop post-hepatectomy liver failure (PHLF) and post SIRT liver failure.

Keywords Hepatobiliary Scintigraphy – Guideline – Nuclear Medicine – HPB Surgery – Radioembolization – Selective Internal Radiation Therapy – Cancer
**Abbreviations**

ALAT  
Alanine transaminase

ALPPS  
Associating Liver Partition and Portal vein Ligation for Staged hepatectomy

ASAT  
Aspartate aminotransferase

AUC  
Areas under the curve

BSA  
Body surface area

EANM  
European Association of Nuclear Medicine

$^{13}$C  
Carbon-13

CT  
Computed tomography

FDG  
Fluorodeoxy glucose

FOV  
Field of view

FLR  
Future liver remnant

FLRF  
Future liver remnant function

FLRV  
Future liver remnant volume

GGT  
Gamma-glutamyl transferase

HBS  
Hepatobiliary scintigraphy

HCC  
Hepatocellular carcinoma

HPB  
Hepato pancreatico biliary

IDA  
Iminodiacetic acid

IHPBA  
International Hepato-Pancreato Biliary Association

INR  
International normalized ratio

IQR  
Interquartile range

ISGLS  
International study group for liver surgery

KGR  
Kinetic growth rate

MELD  
Model for end-stage liver disease

MUR  
Mebrofenin uptake rate

MRP  
Multi resistant protein

NTCP  
Sodium (Na) taurocholate co-transporting polypeptide

OATP  
Organic anion transporting polypeptides

PHLF  
Post-hepatectomy liver failure

PT  
Prothrombin time

PTT  
Partial thromboplastin time

PVE  
Portal vein embolization

ROI  
Region of interest

SNMMI  
Society of Nuclear Medicine and Molecular Imaging

SIRT  
Selective internal radiation therapy

SPECT  
Single photon emission computed tomography

$^{99m}$Tc  
Technetium-99m

Te-GSA  
Technetium galactosyl serum albumin

TLF  
Total liver function

TNM  
Tumor (T), nodes (N), and metastases (M)
Background

Liver resection is a widely applied procedure and serves as the best option for cure intervention in primary and secondary liver malignancies. With a mortality rate below 5%, major liver resection (≥ 3) according to the Brisbane classification, is an established safe procedure (1, 2). Complications with resection limits arise when the FLR volume (FLRV) subsides below 30%, depending on the parenchymal status and factors related to liver function (3). An increase in mortality (4-16%) is seen when extensive resection results in critically small size liver remnant volumes (4-7). A small FLR increases the risk of post-hepatectomy liver failure (PHLF) (5). Severe postoperative complications and possible intensive care admission are observed in the vast majority of affected patients (3). In the event of primary PHLF, abdominal sepsis, portal vein and arterial thrombosis are found to be mainly at cause (8). In addition, severe blood loss (>2000 mL) and absence of FLR assessment were identified as independent risk factors for primary liver failure. Alternatively, liver failure was found to be exclusively related to an insufficient liver reserve caused by excessive resection of liver parenchyma (9). Therefore, in order to avoid this life-treating complication, an emphasis is made on the importance of the preoperative assessment of liver function in the risk evaluation in patients scheduled for resection.

Diagnostic standards mainly rely on computed tomography (CT)-volumetry in the determination of the FLR (10, 11). Volumetry substitutes fairly well for liver function and accurately predicts postoperative outcome in most patients. Nevertheless, volume only substitutes properly in healthy liver parenchyma and under the assumption that function is homogeneously distributed throughout the liver. Unfortunately, in patients with compromised liver parenchyma (e.g., steatosis, cirrhosis, cholestasis, chemotherapy induced damage) volume ceases to correlate well with function (12). As a result, the actual liver function is either over- or underestimated leading to a wrongful determination of the FLR function (FLRF) (13, 14). To circumvent the inaccurate substitution of volume for function, several quantitative function-based methods are developed (15). The indocyanine green clearance test and the LiMAx $^{13}$C-methacetin breath test provide quantitative information on liver function. Still these methods
merely reflect global liver function, offering no information on regional variations in functional distribution portrayed in patients with compromised liver parenchyma.

The introduction of HBS using single photon emission computed tomography (SPECT)/CT provides a solution to reliably assess regional function variation. Anatomical mapping by fusion of SPECT and CT images allows for an accurate analysis of regional liver function. Performing HBS with $[^{99m}\text{Tc}]\text{Tc}$-galactosyl human serum albumin (Tc-GSA) is widely applied in South-East Asia. However, the fact that it is not approved for clinical use in most Western countries and its limited availability renders $[^{99m}\text{Tc}]\text{Tc}$-GSA unsuitable for global application. Alternatively, $[^{99m}\text{Tc}]\text{Tc}$-mebrofenin is widespread available and approved for global clinical use. Calculation of the mebrofenin uptake rate accurately reflects total liver function (16). The hepatic uptake of mebrofenin has been correlated ($r = 0.73$, $P < 0.0001$) (17) with indocyanine green and shows similar transporter specificity (18). The selective uptake of mebrofenin by hepatocytes in combination with SPECT/CT fusion allows segmental evaluation of liver function. Therefore, HBS is advised as assessment of regional liver function to prevent post SIRT liver failure and PHLF (19-23).

Although not supported by evidence from randomized trials, preoperative assessment carried out by HBS appears to be more reliable to estimate the risk of PHLF and liver failure-related mortalities after liver resection than assessment by CT volumetry (13, 15, 23-26). Liver failure and liver failure-related morbidity were both found to be significantly correlated to FLRF in contrast to CT volumetry. Conversely, when comparing volumetric and functional cut-off values, either sufficient FLRV or FLRF values may conflict with each other and result in misinterpretation of the FLR and possible invalid withholding of an otherwise by HBS defined safe resection (27, 28). Therefore, in addition to CT- or MRI-volumetry, assessment of regional liver function through HBS or similar diagnostic methods are advised to be implemented in the preoperative assessment before liver resection (29, 30). Already HBS is an increasingly applied clinical diagnostic measurement in the preoperative risk analysis of patients with an indication to undergo liver resection. Despite the fact that the use of HBS is associated with a decreased risk of PHLF, surgeons should be aware that patients are at risk of being withheld a potentially
feasible resection based on borderline-insufficient function. This should be weighed in the context of potential oncological benefit and other clinical parameters. However, insufficient function contra-indicates resection and points to limited survival. Attention for quality of life in end stage disease is an increasingly important aspect of medicine and urges appropriate palliative care.

Accurate demarcation of the resection margins on the preoperative images delineates the FLR to estimate the FLRF, providing a reliable preoperative prediction of postoperative liver function (31). Regional quantification improves the predictive value, for it considers the heterogeneity in the distribution of liver function. Patients with a FLRF below the cut-off value of 2.7%/min/m\(^2\) are more at risk of developing complications related to PHLF (12, 20). Dependent on the extent of insufficiency of the FLRF, several regenerative procedures to preoperatively increase the FLR and/or FLRF are proposed to decrease risk of PHLF (12, 20, 32).

In the vast majority of expert hepatobiliary surgery centers portal vein embolization (PVE) is considered the standard of care for increasing FLR before major resections (33). Augmentation through associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is recommended when FLR estimates following PVE are predicted to induce insufficient FLR hypertrophy to ensure adequate capacity for safe resection.

Structured application of preoperative PVE is suggested to contribute a major role in the decrease of liver failure and mortality rates (21, 23). However careful consideration of patients at risk for poor outcome is necessary to prevent insufficient post-PVE hypertrophy. In this case HBS can be used as a predictor to select patients for ALPPS or to refrain from FLR augmentation completely (34). An increase in function of 1%/min/m\(^2\) (IQR, 0.60-1.56) after PVE is reported in a mixed cohort of primary and secondary liver tumors. FLRF and total liver function values should be evaluated to estimate PVE success rates. This may prevent unnecessary procedures that lead to insufficient induction of hypertrophy for safe resection (34). Additionally, assessment of the kinetic growth rate (KGR) expressed
as volumetric increase per week expressed after ALPPS stage 1 is performed to estimate the risk for PHLF according to the “50-50 criteria” defined as prothrombin time <50% and serum bilirubin >50μmol/L on postoperative day 5, and the comprehensive international study group for liver surgery (ISGLS) criteria (35-37). A significant reduction in risk for PHLF was found in patients where KGR of the FLR was ≥ 6%/day (36). Future investigations to determine the increase in function and the predictive value it has regarding the risk for PHLF in regenerative procedures may refine selection to increase the successful fraction of patients with sufficient post-procedural FLR. Furthermore, identification and comprehension of potential factors that inhibit functional increase might lead to a more accurate prediction of a sufficient FLRF.

In patients eligible for SIRT, assessment of liver function by HBS may improve risk evaluation and radionuclide treatment planning. SIRT is an evolving therapeutic modality, characterized by selective intra-arterial radioembolization with 90Ytrium- or 166Holmium microspheres. The technique predominantly targets tumorous tissue, however, inevitable radiation damage to the non-tumorous liver tissue caused by SIRT may decrease liver function of the considered healthy parenchyma. The additional deterioration of healthy liver tissue further decreases liver function and increases risk for post-SIRT liver failure. Moreover, patients candidate for SIRT frequently present with parenchymal liver disease, further jeopardizing liver capacity. Currently used tools to estimate liver function in the work-up for SIRT include blood tests, clinical evaluation and prognostic models (i.e. Child-Pugh, MELD). Patients eligible for SIRT largely suffer from parenchymal disease and thus portray regional variation in the distribution of liver function. Although limited, preliminary studies reporting on the superiority of predicting liver dysfunction with HBS over liver volumetry in monitoring functional reserve after SIRT in patients with hepatocellular carcinoma (HCC) have been conducted (20, 38, 39).

**Clinical indications**

Patients scheduled for major liver resection (≥ 3) according to the Brisbane classification (40), with a serum bilirubin level < 50 μmol/L (2.92 mg/dL) may benefit from HBS, especially when indications for
an inhomogeneous distribution of liver function are present and in patients considered for SIRT with liver function affecting hepatic comorbidity. Serum bilirubin levels need careful monitoring when HBS is indicated, as hepatic uptake of $[^{99m}Tc]$Tc-mebrofenin in the presence of high bilirubin falsely reflects decreased hepatocyte function. It is recommended that no other nuclear medicine examination is performed in the 48 hours for technetium and 24 hours for FDG before HBS that could be misperceived as activity in the liver. The pretest high likelihood of false insufficient FLRF warrants postponing the acquisition until bilirubin levels decrease under conditions with reversible hyperbilirubinemia (e.g. after biliary drainage). The volumetric threshold for healthy liver parenchyma has roughly been set on a FLR of 25% of the total liver volume, considering clinical parameters are favorable. A FLRV of at least 40% is preferred in diseased liver parenchyma (e.g. steatosis cirrhosis, cholestasis, chemotherapy induced damage) to maintain proper postoperative liver function (41). FLRV misestimates occur more frequently in high-risk patients, as function is more heterogeneously distributed throughout compromised livers. In these patients, rigid cutoff values for volume may oust patients from curative resection. Instead, FLRF values above cutoff still suggest safe curative resection, without increased risk of PHLF. Therefore, an additional diagnostic angle of approach is required. The advantage of HBS provides a universal cut-off value which can be applied in both healthy and compromised livers. The current clinical cut-off to pursue safe surgical resection resides at the initial value of 2.7%/min/m$^2$ while considerate variations in the clinical setting are observed. The only absolute contraindication for HBS is limited to history of severe anaphylactic reaction to $[^{99m}Tc]$Tc-mebrofenin, however this is extremely rare (42).

**Considerations**

The following considerations have led to the inclusion of HBS in the preoperative risk analysis of patients with an indication for liver resection, additional to volumetry, clinical grading systems and TNM staging.

1. Volumetric assessment alone fails to identify and distinguish patients with a reduced (regional) liver function, as volumetric measurement is unable to distinguish the difference between the
parenchymal status of diseased livers and healthy livers. Extensive surgery pushes the boundaries of safe resections and requires a precise determination of the remaining functional liver capacity. Initially HBS will determine a global overview in liver function. Combined with anatomical mapping and the suggested resection margins, the FLRF value may provide additional information in determining sufficient capacity of the FLR to support normal liver and regenerative function to recover from surgery without increased risk for PHLF.

2. Distinction between low- and high-risk patients following HBS identification will reveal patients prone to develop PHLF and liver failure related complications. High-risk patients may either be selected for regenerative procedures such as PVE and ALLPS or in some cases will be completely deemed unfit for surgery.

3. Evaluation of PVE and ALPPS is complemented by HBS as a result of the strong redistribution of liver function that has been induced by embolization of the contralateral liver. The effectiveness of the hypertrophic response is measured through assessment of the KGR. Although ALPPS conveys a strong hypertrophic response, the relatively high rate of PHLF following resection is thought to be explained by the volumetric hypertrophy that exceeds the functional increase in reaching their target value. The lag of actual liver function is thereby missed in volumetry-only based assessment; as not all additional liver volume exhibits equal liver function. In contrast, an underestimation of function by volume-only assessment has been found in PVE patients. Consequently, surgery can potentially be scheduled more timely as result of the discrepancy between volume and function after PVE or ALPPS.

4. Pre-SIRT risk-evaluation by HBS may be advised, as a result of the regional distribution of function in patients caused by underlying liver disease (e.g. cirrhosis in HCC; chemotherapy). Additionally, after SIRT the susceptibility to liver insufficiency is temporarily increased by the decrease in liver function. The proposed segments for SIRT can be assessed by ability of HBS to perform measurement of regional liver function to predict the risk of post SIRT liver failure before the intervention. To anticipate high-risk predictions, SIRT can be performed in two sessions to allows the regeneration of individual segments in between. The measurement of healthy parenchyma function can be used to refine normal tissue complication probability
models for SIRT, absorbed dosage could be correlated to the decrease in liver function and allows the prediction of post-SIRT global liver function.

Additional aspects currently under investigation should also be noticed.

5. Further distinction within tumor groups will provide specification in risk factors of HBS. For instance biliary excretion may provide additional information in the risk analysis in patients with possible post-hepatic obstruction (e.g. central or extrahepatic cholangiocarcinoma).

6. Two trials (HYPER-LIV01 & DRAGON1) are currently ongoing where PVE alone is compared with simultaneous PVE and hepatic vein embolization. The double vein embolization method is postulated to lead to increased hypertrophy and resectability (43, 44). The disparity between the volumetric increase and functional increase that is seen after PVE and ALPPS will be investigated for simultaneous double vein embolization.

**Procedure request**

The uniformity of the procedure facilitates the request following the clinical indication. Patient distinction will occur during the interpretation process, depending on the tumor location and the thereby proposed resection (e.g. left or right (extended) hepatectomy with or without segment 1, 4a and 4b). The request encompasses all for HBS clinically necessary information. This includes patient history regarding previous interventions encompassing the following: ablation, segmentectomy, SIRT, regenerative procedures and chemo- and/or bland embolization; past and/or planned neoadjuvant chemotherapeutic agent and number of administered cycles; parenchymal liver diseases; planned treatment; planned resection of segments; tumor type, both primary and/or secondary; parenchymal diseases; relevant laboratory values (ASAT, ALAT, GGT, bilirubin, alkaline phosphatase, albumin, PT, INR and PTT); potential interacting medication.

**Protocol**

**Patient preparation and precautions**
Patient preparation is essential for consistency and reproducibility. The pharmacokinetic condition of the liver should be as uniform as possible since uptake of \(^{99m}\text{Tc}\)-mebrofenin is affected by blood flow. Therefore acquisition after a minimum period of 4 hours of fasting is essential to perform measurements in the presumable resting state of the hepatocytes (45). Conversely, prolonged fasting exceeding 24 hours must be prevented as biliary kinetics are altered significantly (46). Diabetic patients are preferably scanned early in the morning.

**Radiopharmaceutical (\(^{99m}\text{Tc}\)-mebrofenin)**

The administered radiopharmaceutical of interest is \(^{99m}\text{Tc}\)-mebrofenin (2,4,6 trimethyl-3-bromoiminodiacetic acid). This iminodiacetic acid (IDA) agent is a lidocaine analogue with lipophilic properties and is taken up by hepatocytes and eliminated through the biliary tract. It allows non-invasive examination of the hepatobiliary system. Of all IDA analogues, \(^{99m}\text{Tc}\)-mebrofenin exhibits the highest hepatic uptake with minimal urinary excretion and strong resistance to displacement by elevated serum bilirubin levels (47). The almost exclusive uptake and excretion of \(^{99m}\text{Tc}\)-mebrofenin by the liver eliminates extrahepatic interference, characterizing it as most suitable radiopharmaceutical for the evaluation of liver function. There is a significant underestimation of mebrofenin scintigraphic liver clearance with increasing labeling-to-administration time. If liver function assessment is the purpose of a hepatobiliary study, \(^{99m}\text{Tc}\)-mebrofenin should be administered as close to the time of radiopharmaceutical preparation as possible, preferably within 1 hour (48). For the evaluation of liver function, the only cut-off values that are validated are those obtained with \(^{99m}\text{Tc}\)-mebrofenin. Therefore, measurement of the hepatic uptake using all alternative radiolabeled IDA agents is strongly discouraged.

**\(^{99m}\text{Tc}\)-mebrofenin interactions**

Hepatic uptake of \(^{99m}\text{Tc}\)-mebrofenin is impaired in case of elevated serum bilirubin levels ( > 50 μmol/L) as a result of competitive uptake. Both molecules mainly follow the organic anion transporting polypeptides (OATP)1B1 and OATP1B3-mediated uptake, and predominantly multi resistant protein
(MRP)2 excretion into the bile (Figure 1) (18, 23, 49, 50). It is hypothesized that bilirubin pharmacokinetics alter in cholestatic patients as a result of the predominant transportation of conjugated bile salts by sodium (Na) taurocholate co-transporting polypeptide (NTCP). Under these circumstances these bile salts are redirected into the sinusoidal blood and further downstream taken up by hepatocytes for bile excretion called hepatocyte hopping (50, 51). In addition, OATP membrane transporters responsible for bilirubin uptake are downregulated under cholestatic conditions (52). Whether the measured \[^{99m}\text{Tc}\]Tc-mebrofenin uptake rate under these circumstances is an accurate or inaccurate representation of the actual hepatocyte function or an underestimation is subject of debate and needs further investigation.

Also severe hypoalbuminemia affects hepatic uptake of \[^{99m}\text{Tc}\]Tc-mebrofenin and consequentially increases renal excretion. \[^{99m}\text{Tc}\]Tc-mebrofenin binds to albumin when transported though the blood, dissociates in the perisinusoidal space of Disse and is taken up into the hepatocytes (Figure 2). When extremely low serum albumin levels are present, less \[^{99m}\text{Tc}\]Tc-mebrofenin enters the liver. Additionally, the affinity of \[^{99m}\text{Tc}\]Tc-mebrofenin to albumin relative to bilirubin is substantially lower leading to stronger competition between the substances (53).

Lastly, several drug classes interact with OATP and MRP hepatocyte transporters, which potentially alter \[^{99m}\text{Tc}\]Tc-mebrofenin uptake and excretion kinetics (54). Abstinence of OATPs inhibitory agents (e.g. immunosuppressors, rifampicin-antibiotics, antivirals) and MRP inhibitory agents (e.g. antivirals, cytostatic and antipsychotic agents) before HBS acquisition is instructed (55, 56).

**Positioning**

The patient is in supine position during the entire procedure. The patient is positioned on a dual-head SPECT/CT camera with the detectors in anterior-posterior position and the cardiac mediastinum and the liver in the field of view (FOV). The heart, liver and biliary tract up to the choledochus all are required to be in the FOV. An intravenous line, preferably with a 3-way tap is inserted in a vein of the preferred
The arm should be comfortably positioned, but out of the FOV to prevent interference. The arm is slightly elevated at 25°-30° and rests in place for the first dynamic acquisition to maintain continuous venous flow. For SPECT-CT, the arms should be comfortably positioned above the head. If necessary, the FOV can be modified before t = 150 seconds due to the lag time between the radiopharmaceutical injection and the hepatic uptake phase measurement window.

**Acquisition**

During the entire acquisition, no breath holds are performed. Two dynamic acquisitions are performed for measurement of the hepatic uptake phase and the biliary excretion phase. After the first dynamic acquisition, when the accumulation of the tracer has peaked, a fast SPECT/CT of the liver is performed. A correct way of positioning ensures continuous reproducibility of the process. Furthermore, the detectors need to be positioned before injection, so optimal positioning to include liver and heart is warranted.

**Hepatic uptake (phase 1)**

A dual head gamma camera is equipped with low-energy high resolution collimators. The energy window is set symmetrical around 140 KeV. The dynamic acquisition starts with the hepatic uptake phase and is initiated directly after the intravenous bolus injection of the radiopharmaceutical (200 MBq; 5.41 mCi). Here the extraction of tracer from the blood and the subsequent accumulation of the tracer in hepatocytes is monitored. The acquisition parameter settings are as followed: 38 frames of 10s/frame in matrix size 128 x 128, no zoom. This results in 2 spare (expendable) frames at start (the Ekman formula requires 36 frames of 10 sec) enabling to normalize the dataset ensuring the frame showing appearance of activity within the abdominal aorta can be selected as the first frame for quantification.

**SPECT/CT acquisition (phase 2)**

In between the dynamic phases, a fast multiple angle 360° acquisition is performed to map the three-dimensional distribution of the radiopharmaceutical in the state of peak hepatic uptake. The
recommended acquisition parameters are as followed: 60 frames (30 per head) of 8 s/frame in matrix size 256 × 256, zoom 1.0. For anatomical mapping fusion of SPECT with CT imaging, an additional low-dose non contrast CT scan is performed. In centers equipped with IV contrast on SPECT/CT, using IV contrast could be considered, allowing better anatomical delineation on the CT.

**Biliary excretion phase (phase 3)**

The dynamic acquisition continues with the biliary excretion phase. It is performed in the same patient position and immediately succeeds the SPECT/CT acquisition. The acquisition parameter settings are as followed: 20 frames of 60 s/frame in matrix size 128×128, no zoom.

**Post-processing**

**Signal attenuation correction**

Differences in signal intensity are detected when the anterior and posterior datasets are compared, caused by the anterior location of the left liver lobes (S2-3) relative to the cameras and the decrease in signal strength over distance (so called attenuation). To correct for the differences, a geometric mean ($G_{mean}$) of the combined datasets is calculated with the given formula for a more accurate estimation of the actual signal intensity.

$$G_{mean} = \sqrt{\text{anterior} \times \text{posterior}}$$

**Masking**

Ideally post-processing is conducted in the state of peak hepatic uptake of the tracer. In case of rapid uptake and excretion of the tracer the SPECT acquisition will extend into the excretion phase, portraying biliary accumulation of the tracer. Biliary activity, either intrahepatic or extrahepatic, wrongfully increases the SPECT signal and impedes calculation of the TLF (Figure 3). Biliary activity is not representative for the hepatic uptake and requires masking. The extrahepatic biliary ducts are defined as extrahepatic activity and completely replaced with a zero activity voxel count, whereas intrahepatic activity is replaced with the average signal intensity of the surrounding parenchyma.
Processing of dynamic planar images to determine total liver function

The first image in the hepatic uptake phase where radiopharmaceutical inflow in the aorta is detected, determines the universal starting point to ensure that all post-processing is done in similar timespan (Figure 4). Imaging prior to the starting point is discarded. To clarify, when starting with post-processing of the dynamic planar images in the workflow, the selected files for post processing must be included: SPECT imaging (phase 2), low-dose CT for the demarcation of the resection margins and the corrected hepatic uptake phase (phase 1) in anterior and posterior view. The first step of post-processing comprises the selection of the Region Of Interest (ROI) to determine the total and specific activity within the FOV. Delineation of the left ventricle demarcating strictly around the high signal intensity borders on the first image defines the first ROI, the blood pool (Figure 5). The liver can be delineated semiautomatically, depending on the software package and forms the second ROI (Figure 5). Position the blood pool and liver regions with caution to prevent overlapping of the ROIs and incorrect summation of hepatic and cardiac activity. The last ROI is drawn automatically, enclosing the full FOV to define the total body activity. The time-activity curves of the ROIs are individually plotted in the graph (Figure 6). The \[^{99mTc}\]Tc-mebrofenin hepatic uptake rate is derived from the differential gradient of the liver signal activity curve. Once all ROIs are defined, the TLF (%/min) is automatically calculated based on the Ekman formula on dynamic scans (57). The TLF as well as the FLRF normalized to body surface area (BSA) (%/min/m²) to account for individual metabolic rate is calculated based on the Mosteller formula (58).

Processing of SPECT/CT to determine regional liver function and FLRF

The determined ROI of the liver in the hepatic uptake phase must be translated to SPECT to derive the functional share of the FLR. Delineation of the volume of interest generates the 3D functional distribution. To conduct surgical planning on the SPECT/CT fusion and determine FLRF values, the demarcation of resections margins translates the ratio of sum of voxel counts from the functional share to the total liver function. Delineation of the resection margins demarcates the FLR and should be done so according to the Couinaud classification (Figure 7) (59). The FLRF can be computed by multiplying
the count fraction of the FLR compared to the total liver times the FLR. A FLRF greater than 2.7%/min/m\(^2\) is advised to avert increased risk of PHLF. Similarly, in patients with perihilar cholangiocarcinoma, a cut-off value for liver function of 8.5% was determined as normalization BSA was found to have no added predictive value for PHLF (23).

**Biliary excretion rate**

The biliary excretion is monitored in the second dynamic phase and is used to calculate the biliary excretion rate. The biliary excretion rate is calculated from the difference in count ratio in a representative peripheral liver ROI on the first and last frame and expressed in %/min using the following formula:

\[
\frac{ROI_{frame20} - ROI_{frame1}}{20} \times 100\%
\]

Excretion rates below 0.5%/min in a patient with a reasonably good hepatic uptake rate can be indicative for obstruction and requires further diagnostic assessment. In patients with a very low hepatic uptake rate, excretion cannot be adequately assessed.

**Cut-off values**

The derivation of the initial and current cut-off of 2.7%/min/m\(^2\) is based on limited data from a small mixed cohort of 55 patients with predominantly biliary tumors (12). Additionally, the HBS cut-off value is derived from a general population of patients preceding liver resection and therefore set at the higher end (21). HBS accounts for the presence of underlying parenchymal liver disease, thereby instating 2.7%/min/m\(^2\) as a universal cut-off value. Despite the fact that the cut-off is merely based on a small mixed cohort, a significant decrease in the occurrence of PHLF has been achieved. However the cause of post hepatectomy liver failure (PHLF) is multifactorial, stressing the importance of additional patient, disease and surgical related predictive factors in the risk analysis (8, 60). Including the fact that liver function is multifactorial as well and the fact that HBS merely monitors the uptake and excretion of bilirubin, variation in cut-off values in the clinical setting are anticipated (18, 61). Several studies have
reported a redefinition or validation of initial cut-off value either based on the “50-50 criteria” or the comprehensive “ISGLS criteria” (24, 35, 37, 62-64). An additional cut-off value of 8.5%/min was determined for patients suspected of perihilar cholangiocarcinoma (23). In this case normalization for BSA attained no additional benefit in the prediction for PHLF. In the initial cohort only the normalized to BSA cut-off value was included in the prediction for PHLF hampering the discussion concerning the additional benefit of normalization (12). Altogether, further specification of the cut-off values and determining the added benefit of normalization in distinct tumor types and in patients with underlying parenchymal disease is essential. Tumor and patient specific validation offers previously labelled unresectable patients a more personalized preoperative prediction of PHLF for resection without increasing morbidity and mortality. Altogether, further specification of the cut-off values and determining the added benefit of normalization in distinct tumor types and in patients with underlying parenchymal disease is essential. Tumor and patient specific validation offers previously labelled unresectable patients a more personalized preoperative prediction of PHLF for resection without increasing morbidity and mortality.

**Documenting/Reporting**

The interpretation of the HBS scans are preferably reported by a nuclear medicine physician and/or radiologist with an expertise in HBS documentation. The report should always include a fusion of the SPECT/CT images as anatomical mapping for the display of regional variations in functional distribution is of interest for the hepatobiliary surgeon. The report should always include a summary of the procedure, commencing with a description of the first phase (liver perfusion) and an indication of the quality of the hepatic uptake of the radiopharmaceutical (second phase). This should be followed by an evaluation of the third phase: the excretion into the biliary tract, the intestinal outflow and the clearance. The variables that should be documented represent the total liver function (%/min), the FLRF (%/min/m²) with the corresponding segments and the bile excretion of these segments (%/min). Relevant results from previous scans should be included, including the numerical values of the previous examination to determine an increase or decrease in liver function.
Software

To process scintigraphic and SPECT/CT acquisitions, a variety of software programs are available on the market, which have been validated for the calculations of MUR and are capable of determining total and regional liver function using formulas for liver clearance according to Ekman et al (65). The dynamic SPECT and CT acquisitions can be shown and analyzed using the software’s integrated workflow. Hepatic uptake is based on Gmean, and automatically derived from the anterior and posterior dynamic data sets. Within the same procedure, the SPECT and CT images are combined and visualized.

Hardware

A dual-headed SPECT/CT gamma camera equipped with a low-energy, high-resolution parallel-hole collimator is endorsed. The energy window is positioned on the photon peak of $^{99m}$Tc (140 keV) at 15% or 20%. The CT component can be used as either an optimized diagnostic CT scan or for attenuation correction and anatomical localization. Use of a low milliampere-seconds setting (low dose CT) is advised to reduce the radiation dosage to the patient if the CT scan is directed for attenuation correction and anatomical localization. Operators should be aware of the characteristics particular to their scanner as well as the range of settings that are consistent with achieving the required image quality and reference dosage values.

Literature perspectives

The initial study by De Graaf et al. (12) assessed the accuracy of HBS to predict PHLF in a population of high-risk patients requiring major hepatectomy. The correlation between the preoperatively predicted FLRF and the actual postoperative remnant liver function measured within 3 days was strong (Pearson $r = 0.83$, $P < 0.0001$). In addition, the relationship between FLRV and FLRF in healthy and compromised parenchyma was performed. This revealed the poor substitution of FLRV for FLRF in compromised liver parenchyma. Namely, FLRV showed a strong correlation with FLRF in healthy parenchyma (Pearson $r = 0.72$, $P < 0.0001$) and showed moderate correlation in compromised parenchyma (Pearson $r = 0.61$, $P < 0.0003$). The ROC analysis determined sensitivity (89%) and specificity (87%) for the
FLRF cutoff value of 2.69 %/min/m² to identify patients prone to develop PHLF. Patients with a value above this threshold had a 2.4% risk for PHLF (NPV = 97.7%, negative likelihood ratio = 0.12).

A follow-up study was performed by Dinant et al. (24) to compare the FLRF measured by HBS with the FLRV measured by CT-volumetry. The Area Under the Curve (AUC) values representing the predictive value for liver failure of FLRF was 0.90 (95% CI, 0.80-1.00) vs. 0.65 (95% CI, 0.37-93) for FLRV. The predictive value for liver failure-related mortality was 0.88 (0.75-1.00) for FLRF vs. 0.61 (0.21-1.00) for FLRV.

In a study by Olthof et al (13), the increase in FLRV with the increase in FLRF was compared in 60 patients that underwent ALLPS evaluated by CT-volumetry and HBS. When comparing the parameters of liver volume with function, the AUC representing the predictive value of FLRF were 0.60 (95% CI, 0.30-0.90) for liver failure, 0.63 (0.49-0.78) for major morbidity, and 0.74 (0.50-0.98) for mortality in comparison with the AUC representing the predictive value of FLRV% was 0.51 (95% CI, 0.26-0.76) for liver failure, 0.54 (95% CI, 0.38-0.70) for major morbidity and 0.72 (0.45-0.99) for mortality.

**Qualifications and responsibilities of personnel**

**Physicians**

HBS diagnostics is an interdisciplinary field at the intersection of HPB surgery, general-, interventional radiology and nuclear medicine. A close collaboration between these fields and a mutual understanding of both radiological and surgical aspects will lead to a more personalized and targeted treatment. Surgeons will determine the resection margins of the patient. Subsequently the nuclear medicine physician delineates the according segments and calculates the remnant liver function and provides an estimation on the preoperative risk for PHLF based on the FLRF. Regenerative procedures will be recommended when the segments show a function below the cutoff rate. Evaluation of these regenerative procedures will also be based on HBS to see if the gain in function has been sufficient. Physicians will work in the same workflow containing SPECT and CT images and the surgeon and nuclear medicine physician together settle on a surgical plan.
Technologists

Nuclear medicine technologists need specific training to be qualified for the acquisition of HBS. The acquisition protocol is uniform and is carried out in the same manner for all patients. Nuclear medicine technologists bear responsibility for the entire image acquisition process. This includes preparing the patients, both physically and mentally since the process lasts approximately 45 minutes. Sustaining comfort for the patient is essential to provide a qualitative scan results. Therefore, the positioning of the patient is an important aspect.

The general condition and state of quality of the hardware installation must be checked and monitored regularly. Also, the technologist is involved in the patient scheduling, the ordering and/or preparing the radiopharmaceutical, proper intravenous injection and correct protocol execution, including the reconstruction and image processing. NM examinations should be executed by qualified registered/certified Nuclear Medicine Technologists. Please refer to: Performance Responsibility and Guidelines for Nuclear Medicine Technologists 3.1 and http://www.eanm.org/content-eanm/uploads/2016/11/EANM_2017_TC_Benchmark.pdf for further details.

Physicists and IT personnel

All included personnel should be included in the multidisciplinary approach. Quality control of the equipment, which falls under specified responsibility of the technical support group (which may include technologists) or the medical physicist for both the nuclear medicine and the interventional radiology department must be maintained.

Equipment specifications, quality control and radiation safety in imaging

Gamma camera quality control must follow national rules or the manufacturer’s instructions. For further guidance on routine quality control procedures for gamma cameras, refer to the SNMMI Guideline for General Imaging and the EANM guideline on routine quality control for nuclear medicine instrumentation. The radioactive concentration should be determined by measuring the activity of the radiopharmaceutical containing vial in a calibrated ionization chamber. Labelling efficiency should be
>95 %. The manufacturer’s instructions for assessment of radiochemical purity (e.g. by thin-layer chromatography) and local laws should be followed. The administration must comply with local applicable guidelines and recommendations and has to be administered by the rapid injection as a bolus via the intravenous route, preferably via an indwelling catheter. Vials, syringes, injection needles and gloves used for injection are stored in lead shielded containers until safe radioactive levels are attained. Side effects or incidents should be reported in accordance with applicable laws. Post-processing of data to obtain the hepatic uptake rate and future remnant liver function aimed at referring to published normal values and cut-off values should be performed according to the guidelines and with a validated application.

**Supplementary information**

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. SNMMI and EANM members include physicians, radiologists, technologists, and scientists specializing in the research and practice of nuclear medicine.

The International Hepato Pancreato-Biliary Association (IHPBA) is a world renowned non-profit organization founded in 1978, dedicated to alleviating global human suffering caused by hepatopancreaticobiliary illnesses through promoting understanding of the causes, investigation and treatment of disorders of the liver pancreas and biliary tree. Also the interchange of clinical and scientific knowledge among surgeons and members of related disciplines working in this field is encouraged.

The SNMMI and EANM periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and improve the quality of service to patients throughout the world. Existing practice guidelines are reviewed for revision or renewal, as appropriate, on their fifth
anniversary or sooner, if indicated. Each practice guideline, representing a joint policy statement by the
SNMMI/EANM, has undergone a thorough consensus process in which existing evidence has been
subjected to extensive review. The SNMMI and EANM recognize that the safe and effective use of
diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in
each document. Reproduction or modification of the published practice guideline by those entities not
providing these services is not authorized.

These guidelines represent an educational tool designed to assist practitioners in providing appropriate
care for patients. They are not inflexible rules or requirements of practice and are not intended, nor
should they be used, to establish a legal standard of care. For these reasons, and those set forth below,
both the SNMMI and the EANM caution against the use of these guidelines in litigation in which the
clinical decisions of a practitioner may be called into question.

The officers and the committees of the IHPBA are committed to providing useful tools and
communications to the member organization with a view to providing improved standards and training
of hepato-pancreato-biliary surgeons.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be
made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no
implication that an approach differing from the guidelines, standing alone, is below the standard of care.
To the contrary, a conscientious practitioner may responsibly adopt a course of action different from
that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action
is indicated by the condition of the patient, limitations of available resources, advances in knowledge or
technology subsequent to publication of the guidelines, local regulatory requirement, or reimbursement
frameworks. The practice of medicine includes both the art and the science of the prevention, diagnosis,
alleviation, and treatment of disease. The variety and complexity of human conditions make it
impossible to always reach the most appropriate diagnosis or to predict with certainty a particular
response to treatment.
Therefore, it should be recognized that adherence to these guidelines will not guarantee a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.

Members of the EANM Oncology Committee (Christophe Deroose, Nevena Manevska and Lioe-Fee de Geus-Oei) and the SNMMI representatives (Renee Moadel and Charles Marcus) invited the IHPBA Research Committee (represented by Fabrizio Panaro, Christian Sturesson and Joris Erdmann) and a senior and junior expert (Roel Bennink, Pieter Arntz) to take part in developing this guideline.

1. LIABILITY STATEMENT
This guideline summarizes the views of the EANM Oncology and Theranostics Committee, the SNMMI and IHPBA. It reflects recommendations for which the EANM / SNMMI / IHPBA cannot be held responsible. The recommendations should be taken into context of good practice of the different disciplines (mainly Nuclear Medicine and Hepatobiliary Surgery) and do not substitute for national and international legal or regulatory provisions.

2. ACKNOWLEDGMENT
This guideline was brought to the attention of the EANM Oncology and Theranostics Committee. The comments and suggestions from the SNMMI, IHPBA, EANM Technologists, Physics- and Oncology and Theranostics Committee, and the National Societies of Nuclear Medicine were highly appreciated and have been included in this guideline.

3. COMPLIANCE WITH ETHICAL STANDARDS
- This study received no funding.
- All authors declare no conflict of interest.
Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.

REFERENCES


30. SJ W. Highlights in this issue: Hepatobiliary scintigraphy a major step towards safer liver surgery. HPB. 2016;18(9):ii.
53. Krishnamurthy GT, Krishnamurthy S. Nuclear hepatology: Springer; 2009.


Figure 1. Predominant hepatic uptake (OATP1B1, OATP1B3) from the space of Disse and biliary excretion (MRP2) of $[^{99m}Tc]$mebrofenin into the biliary tract.
Figure 2. [$^{99m}$Tc]Tc-mebrofenin bound to albumin when transported though the blood dissociates in the perisinusoidal space of Disse and is taken up into the hepatocytes.
Figure 3. Result of masking the intra- and extrahepatic tracer activity in the SPECT/CT workflow. From top to bottom; the transversal and coronal plane and the 3D SPECT view. The left images represent the unmasked state with high extrahepatic tracer activity. The right images represent the masked state.
Figure 4. Anterior and Posterior view of the universal starting point. The first image with tracer inflow into the aorta calibrates this point.
Figure 5. delineation of the ROIs. The blood pool demarcated in green, the liver in red.
Figure 6. Graph illustrating the time-activity curves of the 3 ROIs (blood pool, liver, full FOV)
Figure 7. Demarcation of the volume of interest of the total liver and the drawn constraints to determine the FLRF of segments